AI assistant
Sending…
Quoin Pharmaceuticals, Ltd. — Director's Dealing 2024
Sep 11, 2024
35443_dirs_2024-09-11_ce4eff3d-f32c-4b69-aa7a-0a30fe7e9c2b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2024-09-09
Reporting Person: Dunn Gordon (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-09-09 | Ordinary Shares | P | 856 | $0.80 | Acquired | 856 | Direct |
| 2024-09-09 | Ordinary Shares | P | 4000 | $0.78 | Acquired | 4856 | Direct |
| 2024-09-09 | Ordinary Shares | P | 4000 | $0.80 | Acquired | 8856 | Direct |
| 2024-09-10 | Ordinary Shares | P | 10000 | $0.91 | Acquired | 18856 | Direct |
| 2024-09-10 | Ordinary Shares | P | 10000 | $0.71 | Acquired | 28856 | Direct |
Footnotes
F1: Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary shares of the Issuer.
More from Quoin Pharmaceuticals, Ltd.
Regulatory Filings
2026
Jun 4
Regulatory Filings
2026
Jun 2
Interim / Quarterly Report
2026
May 7
Annual Report
2026
Mar 26
Earnings Release
2026
Mar 26
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 11
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 6